Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Journal Volume
32
Journal Issue
11
Start Page
2130
End Page
2132
ISSN
1557-3265
Date Issued
2026-06-01
Author(s)
Abstract
Eribulin was evaluated in angiosarcoma and epithelioid hemangioendothelioma (EHE) through two prospective international trials. Although encouraging activity was observed in EHE, its role in angiosarcoma may depend on further refinement through subgroup selection. These findings underscore the importance of histology-specific interpretation, innovative endpoints, and coordinated strategies for ultrarare sarcoma drug development. See related article by Cote et al., p. 2206.
Type
journal article